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Abstract
As dengue fever is undifferentiated from other febrile illnesses in the tropics and the clinical course is unpredictable,
early diagnosis is important. Several commercial assays to detect dengue NS1 antigen have been developed;
however, their performances vary and data is lacking from hyper-endemic areas where all four serotypes of dengue
are equally represented. To assess the sensitivity of the Bio-Rad platelia Dengue NS1 antigen assay according to
virus serotype, immune status, gender, and parameters of severe disease, acute sera from 220 individuals with
confirmed dengue and 55 individuals with a non-dengue febrile illness were tested using the Bio-Rad platelia Dengue
NS1 antigen assay. The overall sensitivity of the NS1 ELISA was 46.8% and the specificity was 100%. The sensitivity
in primary infections was significantly higher than in secondary infections (100% vs. 35.7%). In secondary infections,
the sensitivity of NS1 detection was highest in DENV-3 (47.1%), followed by DENV-1 (40.9%), DENV-2 (30%) and
DENV-4 (27%) infections. NS1 was less frequently detected in sera with high titers of HI antibodies or in acute
samples from patients whose pre-illness sera showed neutralizing antibodies to more than one serotype. The
detection of NS1 was higher in females, severe cases, and individuals with lower platelet counts (<100,000/mm3).
While the overall sensitivity of this NS1 ELISA is poor, our data suggest that in secondary infections, detection may
be predictive of a more severe illness.
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Introduction
Dengue fever (DF) is a major public health problem with 50
million annual cases worldwide. It has been reported in more
than 100 countries and continues to spread to previously
unaffected regions[1]. DF is caused by dengue viruses
(DENV), which consist of four serotypes: DENV-1, DENV-2,
DENV-3 and DENV-4. Infection with any serotype usually
results in asymptomatic infection or mild non-specific febrile
illness, but in a subset of patients, severe disease develops,
characterized by a transient capillary leakage syndrome
(dengue hemorrhagic fever/ DHF)[2]. This unpredictable
disease course and the need to differentiate DF from other
causes of fever make an early and sensitive diagnosis of acute
dengue virus infection important.
Non-structural 1 protein (NS1) is encoded by the virus and
secreted in a soluble form[3]. Several commercial assays to
detect dengue NS1 have been developed recently[4].
Advantages of NS1 tests are: NS1 is detected early in disease,
several days prior to the appearance of anti-dengue IgM
antibodies[5], and the test is inexpensive, easy, and fast.
Moreover, NS1 levels early in dengue disease have been
correlated with disease severity [6], suggesting that NS1 tests
may also have prognostic value.
Previous studies evaluating the diagnostic value of NS1
antigen assays have had varying results [4,7] (Table S1).
Several factors may account for this: proportion of primary vs.
secondary infections [4,8-11], timing of sample
collection[4,7,8,12,13], infecting serotype[4,7,8,13,14], viremia
levels [6,13,15,16] and severity of illness[6,7,15]. A low
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sensitivity has been reported in secondary infections possibly
due to immune-complex formation of NS1 and pre-existing
antibodies [17]. This may especially be important as the
proportion of secondary infections is expected to rise worldwide
[18]. Although studies evaluating the NS1 assays were
conducted in hyper-endemic areas of Southeast Asia or South
America, in several studies, all four dengue serotypes were not
represented equally [4,7,8,10,13,15,16,19,20] or evaluated
[11,21]. In others, the percentage of primary infections was too
high to represent the situation in hyper-endemic areas
[9,11,12,15,20]. Additionally, only a few studies evaluated the
association between NS1 detection and clinical severity
[4,6,7,15,21]. The objectives of the study were: 1) Determine
diagnostic performance of the Bio-Rad Platelia Dengue NS1
antigen assay in a region where all dengue serotypes circulate
year round and clinical severity could be evaluated 2) Assess
the sensitivity of this assay in secondary cases according to
pre-illness and acute dengue immune status 3) Determine the
sensitivity of this assay according to clinical severity.
Materials and Methods
Ethics Statement
All samples were obtained after written informed consent
through studies approved by the Institutional Review Board of
NAMRU#2 (N2.2006.0001, N2.2004.0010, N2.2004.0008) and
at the National Institute of Health Research and Development,
Ministry of Health, Indonesia (KS.02.01.2.1.2776, KS.
02.01.2.1.3461 and KS.02.01.2.1.2336) in compliance with all
U.S. Federal Regulations governing the protection of human
subjects.
Sample characteristics
Acute sera from archived and fresh samples of 220
confirmed dengue cases and 55 non-dengue febrile illness
cases were used. Samples were from previously published
studies[22,23]. Study one was a prospective dengue cohort
study of ~3,000 factory workers in two factories in Bandung,
Indonesia from 2000-2004 and 2006-2009. Volunteers
participated in serosurveys every three months and visited
factory clinics when they experienced fever. Study two was a
community dengue study where 15-20 people living near a
confirmed dengue case were observed for two weeks when a
dengue case was confirmed at the study hospital. Volunteers in
study one and two were hospitalized when dengue infection
was confirmed. Study three was a hantavirus surveillance
study at two hospitals in Bandung, Indonesia. As clinical
manifestations between dengue and hantavirus are
indistinguishable, samples were screened for evidence of
dengue infection. In all studies, acute sera were collected when
volunteers presented at clinics or hospitals, and convalescent
samples were collected during hospital discharge or 7-10 days
after acute sample collection. Paired samples were tested for
evidence of dengue infection as described below. Complete
blood counts to detect thrombocytopenia and hematocrit
measurements to look for hemoconcentration as one indicator
of plasma leakage were taken daily for hospitalized patients
and upon indication for outpatients. Ultrasonography to detect
plasma leakage was performed on hospitalized patients in
study one and two.
Case Definitions
A dengue infection was confirmed when 1. DENV RNA was
detected by RT-PCR or 2. For RT-PCR negative cases, when
all of the following criteria were met: IgM positive, increasing
IgG titers and a four-fold rise in hemagglutination inhibition (HI)
titers. A primary or secondary dengue infection was determined
by the absence or presence of IgG antibodies in the acute
sample[24]. Non-dengue infection was confirmed when dengue
RT-PCR was negative, and no IgM antibodies, increase in IgG
titers or four-fold increase of HI antibody titers was detected.
Infecting serotypes were determined by RT-PCR and
neutralizing antibodies to each serotype in pre-illness sera
were measured by plaque reduction neutralization test (PRNT).
Dengue cases were classified as DF, DHF, and dengue shock
syndrome (DSS) according to 1999 WHO guidelines[25].
Cases of DF with hemorrhagic manifestations formed a
separate group (DF+HM).
Laboratory tests
Acute serum samples were assayed for DEN virus RNA by
RT-PCR[26]. Acute and convalescent sera were tested for
dengue IgM, IgG and HI antibodies. Dengue IgM and IgG were
detected by capture and indirect ELISA respectively according
to the manufacturer’s instructions (FOCUS Technologies, CA,
USA). HI tests were performed as previously described[27].
Acute samples were tested with the NS1 Platelia antigen
capture ELISA according to the manufacturer’s instructions
(BioRad, CA, USA). PRNT was conducted on pre-illness sera
collected during the serosurvey in study one from 2000-2004.
Three 10-fold serum dilutions were made starting at 1:10 and
diluted samples were assayed as described previously[28]. The
dilution that produced an 80% reduction in plaque count
compared with the negative control sample was determined by
probit analysis using SPSS (SPSS, Chicago, IL). The virus
strains used in the assays were isolated from DEN patients in
Thailand (16001 DENV-1, 16682 DENV-2, and 16562 DENV-3)
and Indonesia (1036 DENV-4).
Statistical analysis
Data were entered into Microsoft Access. Statistical analysis
was performed using STATA version 9 (STATA Corporation,
TX). Categorical variables between two groups were compared
with a chi-square test. A p value of less than 0.05 was
considered significant.
Results
Overall and serotype specific sensitivity of the NS1 test
Samples from 275 volunteers were used, 220 confirmed
dengue cases and 55 non-dengue cases. Dengue infection
was confirmed by both virological and serological evidence in
195 (88.6%) cases and by serological evidence alone in 25
(11.4%) cases. Table 1 summarizes the characteristics, WHO
clinical category, virological and serological data for these
Diagnostic/Prognostic Value of Dengue NS1 Testing
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cases. The overall sensitivity of the assay was 46.8% (95% CI:
40.2-53.3) and the specificity was 100% (55/55) (Table 2). The
sensitivity was 50.3% (95% CI: 43.3-57.3) in samples positive
by RT-PCR, and 20% (95% CI: 4.3-53.7) in samples negative
by RT-PCR. The sensitivity was 100% (34/34) in primary
infections and 35.7% (95% CI: 28.7-42.7) in secondary
infections (p=0.00). In secondary infections, no significant
(p=0.38) difference was found between fresh and archived
specimens (38.9%, 95%CI: 28.8-49 vs.32.6%, 95%CI:
23-42.2); however, the sensitivity by serotype varied. The
highest sensitivity was observed for DENV-3 (47.1%, 95% CI:
35.2-58.9), followed by DENV-1 (40.9%, 95% CI: 20.4-61.4),
DENV-2 (30%, 95% CI: 13.6-46.4) and DENV-4 (27%, 95% CI:
12.7-41.3). This difference in sensitivity was significant when
comparing DENV-3 to DENV-4 (p=0.045.).
NS1 sensitivity according to dengue immune status
To determine if the sensitivity of the NS1 test varied by
dengue immune status, dengue HI titers were determined on
all acute samples and PRNTs were performed on pre-illness
(one to two months prior to dengue infection) sera from the 47
patients enrolled in the first phase of study one. The sensitivity
was significantly (p<0.05) lower in acute samples with high HI
titers (≥1280) compared to samples with lower or undetectable
titers (Table 3A). Among the 47 samples tested by PRNT,
neutralizing antibodies to more than one serotype were
detected in 32 cases and NS1 was only positive in one acute
specimen, giving a sensitivity of 3.1%. In contrast, in patients
with pre-illness neutralizing antibodies to only one serotype, the
sensitivity of the NS1 test was 60% (9/15) (Table 3B). Among
these nine NS1 positive cases, eight had pre-illness
Table 1. Specimen characteristics.
Source of Specimens Study 1 Study 2 Study 3 Total
Non-dengue 51 4 0 55
Acute dengue 125 27 68 220
Mean age in years (range) 36.5 (21-53) 19.5 (4-47) 24.4 (12-50) 30.7 (4-53)
Sex Ratio (male:female) 3.3:1 1:1.1 1.4:1 2.1:1
Outpatients 72 8 0 80
Inpatients 53 19 68 140
Mean day after illness onset (range) 2.7 (1-7) 2 (1-7) 5.1 (2-7) 3.5 (1-7)
Clinical diagnosis (%)     
dengue fever (DF) 84 9 33 126 (57.3)
DF with hemorrhagic manifestations 8 2 22 32 (14.5)
dengue hemorrhagic fever grade I 18 6 5 29 (13.2)
dengue hemorrhagic fever grade II 15 8 8 31 (14.1)
dengue shock syndrome 0 2 0 2 (1)
Infecting serotype (%)     
DENV-1 23 6 6 35 (15.9)
DENV-2 19 5 18 42 (19.1)
DENV-3 35 6 40 81 (36.8)
DENV-4 32 1 4 37 (16.8)
Unknown 16 9 0 25 (11.4)
Type of infection (%)     
Primary 16 5 13 34 (15.4)
Secondary 109 22 51 182 (82.7)
Unknown 0 0 4 4 (1.8)
doi: 10.1371/journal.pone.0080891.t001
Table 2. Sensitivity of the NS1 antigen test according to infection status.
 Infecting serotypes  
Type of infection DENV-1 DENV-2 DENV-3 DENV-4 Unknown* TOTAL
Primary 13/13(100) 11/11(100) 10/10(100) 0/0(0) 0/0(0) 34/34(100)1
Secondary 9/22 (40.9) 9/30 (30) 32/68(47.1)2 10/37(27)2 5/25(20) 65/182(35.7)1
Unknown# 0/0(0) 1/1(100) 3/3(100) 0/0(0) 0/0(0) 4/4(100)
Total 22/35(62.9) 21/42(50) 45/81(55.6) 10/37(27)  5/25(20) 103/220(46.8)
* PCR negative, # IgG results not available,
1. statistically significant difference (p=0.00) 2statistically significant difference (p= 0.04)
doi: 10.1371/journal.pone.0080891.t002
Diagnostic/Prognostic Value of Dengue NS1 Testing
PLOS ONE | www.plosone.org 3 November 2013 | Volume 8 | Issue 11 | e80891
neutralizing antibodies to DENV-2 and one to DENV-1,
whereas among the six negative cases, four had neutralizing
antibodies to DENV-1, one to DENV-3 and one to DENV-2.
The infecting serotypes in eight of the nine positive cases were
DENV-1 (2), DENV-3 (2) and DENV-4 (4).
Table 3. Sensitivity of the NS1 antigen test according to
dengue immune status.
A. Acute specimen HI titer (n=179)
HI titer Sensitivity
< 10 26/32(81.3%)1
10 - 80 29/72 (40.3%)
160 - 640 18/40 (45%)
≥1280 7/35 (22%)1
B. Presence of pre-illness neutralizing antibodies* (n=47)
Number of serotypes Sensitivity
1 9/154 (60%)
more than 1 1/324 (3.1)
1. significantly different from the other groups
*plaque reduction neutralizing antibodies (80%)
4. significantly different from each other
doi: 10.1371/journal.pone.0080891.t003
NS1 sensitivity according to disease severity and
gender
As the sensitivity of the NS1 assay was 100% in primary
infections, only secondary infections were included in this
analysis. The sensitivity among DF cases (25%, 95% CI:
16.7-33.3) was significantly lower compared to DF+HM cases
(55%, 95% CI: 33.2-76.8) and DHF I and DHF II cases (50%,
CI: 36.9-63.1). Additionally, the sensitivity was higher in
patients with platelet counts below 100,000/mm3 at
presentation (48% vs. 27.1%, p=0.00) or at time of platelet
nadir (50% vs.16.2%, p=0.00). A higher sensitivity was also
found in cases with spontaneous hemorrhagic manifestations,
hemoconcentration or effusion, but these differences were not
significant (Figure 1). Data from a subset of patients enrolled in
study one and two in which patients were identified early,
revealed that the mean and range interval between the
detection of NS1 and thrombocytopenia among 28 patients
was 1.8 (0-5) days, whereas the time between the detection of
NS1 and evidence of plasma leakage among 17 DHF patients
was 3.3 (1-5) days. The sensitivity of the NS1 assay was
significantly higher in females than males with values of 49.1%
(95% CI: 36.1-62.1) and 29.6% (95% CI: 21.6-37.6)
respectively (p=0.01). This gender difference remained present
when analysis was restricted to those with manifestations of
more severe disease (Figure 2).
Figure 1.  Sensitivity of the NS1 antigen test according to diagnosis category and clinical variables in secondary dengue
cases.  
doi: 10.1371/journal.pone.0080891.g001
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Discussion
NS1 tests are increasingly being used as a rapid and
inexpensive diagnostic tool for acute DF. We found that its
sensitivity in a dengue hyper-endemic area (Indonesia) where
most infections are secondary was low with an overall
sensitivity of 46.8%. In samples from primary infections, the
sensitivity was 100% indicating that it is a good diagnostic tool
for patients from non-endemic areas, such as in travelers[29].
Our findings are also in line with reports from other countries
that found a low sensitivity in secondary infections [4,13,20].
Apart from primary or secondary infection status, our data also
suggest that sensitivity was affected by dengue immune status,
infecting dengue serotype, gender and severity of illness.
Our data demonstrated poor performance of the NS1 test in
acute sera with high titers of HI dengue antibodies. Further
analysis showed that NS1 antigen was undetectable in nearly
all acute sera from patients with pre-illness neutralizing
antibodies to more than one serotype, but was detectable in
more than half of those with only one serotype. These findings
are in line with the hypothesis that immune-complexes are
formed in secondary infections and high levels of antibodies
capture and bind soluble NS1 (sNS1) resulting in a reduction of
circulating NS1[17]. Therefore, the use of a NS1 assay in areas
where post-secondary dengue infection is common [30,31] has
limited value. The serotype of a previous dengue infection may
also influence the sensitivity of NS1 detection in secondary
infections as we found the sensitivity was significantly higher in
acute samples from patients with pre-illness neutralizing
antibodies to DENV-2 (88.9%) compared to DENV-1 (11.1%). It
has been reported that in comparison to DENV-1 and DENV-3,
DENV-2 infections result in much lower concentrations of
sNS1[32]. Thus, during primary DENV-2 infections, the amount
of sNS1 produced may be unable to generate sufficient NS1
antibodies to form immune-complexes with sNS1 in secondary
infections. The influence of pre-existing antibodies to other
flaviviruses that may circulate in the region such as Japanese
encephalitis as a result of natural infection or vaccination may
also affect the sensitivity of NS1 and should be considered.
The data presented here are consistent with previous studies
that report a higher sensitivity of the NS1 test in DENV-3 and
DENV-1 infections compared to DENV-2 and DENV-4
infections [12,14]. As the specimens used in this study included
all DENV serotypes, the overall sensitivity was not affected by
a predominating serotype as has been reported elsewhere [7].
Our study also demonstrated that in secondary cases, the
sensitivity is better in patients with more severe illness. The
sensitivity of the test in the DF group was significantly lower
compared to the other groups (DF+HM or DHF). DSS cases
were excluded from this analysis, as the number of DSS cases
was too small (n=2). The association between NS1 and clinical
severity has been studied before with discordant
results[4,6,7,15,21]. The differences might be due to
inadequate number of cases[21] or the application of different
clinical category guidelines [4]. NS1 sensitivity was also
significantly higher in patients with platelet counts below
100,000/mm3 measured at presentation only or nadir platelet
counts below 100,000/mm3 if serial measurements were done.
A positive NS1 result in secondary infections may therefore be
a predictor for low platelet count. Although not significantly
different, sensitivity tended to be higher in cases with
spontaneous bleeding, effusion and hemoconcentration. The
association between NS1 and clinical severity is thought to be
related to the cross-reactivity of anti-dengue NS1 antibodies
with platelets and endothelial cells, and the role of NS1 in the
occurrence of vascular leakage through complement and
cytokine responses [33,34]. Recent findings have also shown
Figure 2.  The sensitivity of the NS1 antigen test according to gender and clinical variables in secondary infections.  
doi: 10.1371/journal.pone.0080891.g002
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that NS1 positivity is correlated with higher viremia or
antigenemia which was found in more severe cases[13,15].
The overall sensitivity of the NS1 test and its sensitivity in
secondary infections in our study is lower than what has
previously been published. There are several possible reasons
for this difference. This and other studies have demonstrated
that the sensitivity of NS1 in secondary infections is much
lower than in primary infections. As a consequence, the overall
sensitivity will be affected by the proportion of primary or
secondary infections in the sample set used. Compared to
studies conducted in other endemic countries, our study has a
low proportion of primary infections. Our study also included
outpatients (36.4%). As has previously been reported and is
found in this study, NS1 sensitivity is associated with disease
severity. Therefore, outpatients in our study, which were mostly
mild cases, may have contributed to the lower NS1 sensitivity.
Additionally, we found that among secondary cases, post-
secondary (≥2) cases (cases with pre-illness neutralizing
antibodies to more than one serotype) had lower sensitivities
than secondary cases with pre-illness neutralizing antibodies to
only one serotype. Based upon the data from the 47 subjects
that were tested for pre-illness neutralizing antibodies and the
mean age of our volunteers, we suspect that many of the cases
in our study were post-secondary infections. Finally, the
proportion of secondary infections caused by DENV-2 and
DENV-4, serotypes with lower sensitivities in our study, was
higher than in other studies.
The strengths of this study are: 1) work was conducted in a
setting where all dengue serotypes were equally distributed
and the ratio between primary and secondary infections
reflected the regional epidemiology 2) accurate clinical outputs
were available as patients were monitored closely 3) this study
provides a wealth of laboratory data to assess the correlation
between NS1 detection and serotype distribution, and dengue
immune status including serotype specific pre-existing
immunity, which have not been reported elsewhere. This study
has also several limitations. First, male participants were more
predominant than females. However, despite fewer samples
from females, the detection of NS1 was significantly higher in
females than males. Second, ultrasonography was not
performed on a subset of volunteers. As a consequence,
several DF+HM cases might be more accurately included in the
DHF group. However, the numbers are probably small as daily
hemoconcentration was performed on all individuals. Third,
PRNT was only conducted on pre-illness sera from 47 patients.
Although, the results showed a strong association between
sensitivity and the presence of neutralizing antibodies to
DENV-2, further study is needed.
In conclusion, the NS1 test is not recommended as a
standalone diagnostic test for dengue infection in regions
where secondary infections predominate. However, as the
sensitivity and specificity in acute specimens from primary
infections is excellent, use of the test may prove of value to
travelers returning from dengue endemic areas. Furthermore,
as the sensitivity in secondary cases is associated with clinical
severity, NS1 may be useful to predict severe disease.
However, further studies with larger sample sizes and in other
geographic regions are needed to confirm this association.
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